ELISA/assay

human Interleukin 27, IL-27 ELISA Kit

MBS702498

24-Strip-Wells (LIMIT 1)

240 USD

ELISA Kit

human Interleukin 27, IL-27 ELISA Kit

[interleukin 27]

[human Interleukin 27; IL-27 ELISA Kit; IL-27; IL-27A; IL27p28; IL30; MGC71873; p28; IL-27 p28 subunit; interleukin 30; interleukin-27 subunit alpha; interleukin 27]

[interleukin-27 subunit alpha; Interleukin-27 subunit alpha; interleukin-27 subunit alpha; IL27-A; IL-27-A; interleukin 30; interleukin-30; IL-27 p28 subunit; IL-27 subunit alpha; interleukin 27; Interleukin-30; p28]

[IL27]

[IL27; IL27; p28; IL30; IL-27; IL27A; IL-27A; IL27p28; IL27A; IL30; IL-27 subunit alpha; IL-27-A; IL27-A]

IL27A_HUMAN

Human

243

This assay has high sensitivity and excellent specificity for detection of human IL-23. No significant cross-reactivity or interference between human IL-23 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Tissue Homogenates. Assay Type: Quantitative Sandwich. Detection Range: 6.25 pg/ml-400 pg/ml. Sensitivity: 1.56 pg/ml.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for IL-23 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-23 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for IL-23 is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of IL-23 bound in the initial step. The color development is stopped and the intensity of the color is measured.

28416913

NP_663634.2

NM_145659.3

Q8NEV9

27,493 Da

IL27-mediated Signaling Events Pathway (137929)

The protein encoded by this gene is one of the subunits of a heterodimeric cytokine complex. This protein is related to interleukin 12A (IL12A). It interacts with Epstein-Barr virus induced gene 3 (EBI3), a protein similar to interleukin 12B (IL12B), and forms a complex that has been shown to drive rapid expansion of naive but not memory CD4(+) T cells. The complex is also found to synergize strongly with interleukin 12 to trigger interferon gamma (IFNG) production of naive CD4(+) T cells. The biological effects of this cytokine are mediated by the class I cytokine receptor (WSX1/TCRR). [provided by RefSeq, Jul 2008]

Function: Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication.4 PublicationsManual assertion based on experiment in:Ref.1

24-Strip-Wells (LIMIT 1)

240 USD

48-Strip-Wells

380

96-Strip-Wells

535

5x96-Strip-Wells

2300

10x96-Strip-Wells

4340